1 citations
,
March 2023 in “Science Translational Medicine” Blocking a certain signal in the gp130 receptor can improve tissue healing and lessen osteoarthritis symptoms.
7 citations
,
October 2024 in “Frontiers in Immunology” A humanized CXCL12 antibody may delay and treat alopecia areata by altering the immune response.
March 2019 in “eCommons (Cornell University)” The pony's skin condition improved significantly with prednisolone treatment.
July 2026 in “Journal of the American Academy of Dermatology” 1 citations
,
April 2023 in “Portuguese Journal of Dermatology and Venereology” JAK inhibitors are effective treatments for alopecia areata.
December 2025 in “Cosmoderma” Systemic corticosteroids help manage vitiligo by slowing progression and aiding repigmentation.
June 2024 in “Indian Dermatology Online Journal” Topical tofacitinib is effective and safe for treating alopecia areata.
28 citations
,
December 2001 in “European Journal of Pharmacology” M50054 may help treat hepatitis and hair loss from chemotherapy.
1 citations
,
May 2017 in “Journal of the American Academy of Dermatology” Tofacitinib helped a teenager with severe hair loss grow hair back, but more research is needed.
Anifrolumab improves quality of life and reduces steroid use in lupus patients.
November 2012 in “Annales de Dermatologie et de Vénéréologie” Frontal fibrosing alopecia can occur in children, not just postmenopausal women.
61 citations
,
January 2019 in “American Journal of Clinical Dermatology” The cause of Frontal Fibrosing Alopecia is unclear, diagnosis involves clinical evaluation and various treatments exist, but their effectiveness is uncertain.
November 2020 in “Dubai medical journal” Tofacitinib may effectively regrow hair in alopecia totalis patients.
April 2017 in “Journal of Investigative Dermatology” Fisetin may help treat psoriasis and reduce skin inflammation.
Oral tofacitinib effectively treats alopecia areata long-term with manageable side effects.
1 citations
,
September 2024 in “Life” Combining fractionated CO2 laser with tacrolimus may help treat chronic alopecia areata.
26 citations
,
July 1992 in “International Journal of Dermatology” Oral cyclosporine A and prednisolone effectively improved alopecia universalis without side effects.
1 citations
,
July 2024 in “Journal of Investigative Dermatology” TAK-279 effectively reduces psoriasis symptoms and is safe.
66 citations
,
December 2018 in “Dermatology” Both ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata, but relapses are common.
1 citations
,
November 2023 in “Journal of Investigative Dermatology” Farudodstat may effectively treat alopecia areata without harming hair follicles.
14 citations
,
July 2021 in “Anais brasileiros de dermatologia/Anais Brasileiros de Dermatologia” Interleukin levels are higher in alopecia areata patients but don't predict disease severity or duration.
September 2025 in “Annals of African Medicine”
July 2023 in “Clinical and Experimental Dermatology” Combining baricitinib with low-dose corticosteroids significantly improved severe hair loss in eight patients.
August 2019 in “Journal of the American Academy of Dermatology” Tofacitinib may help hair regrowth in alopecia areata, but more research is needed.
July 2025 in “Journal of Investigative Dermatology” γδ T cells can prevent and treat alopecia areata, offering a new therapy option.
Farudodstat can prevent hair follicle immune damage linked to alopecia areata.
November 2025 in “Journal of Dermatological Treatment” Dexamethasone oral mini-pulse therapy effectively treats severe alopecia areata when JAK inhibitors can't be used.
10 citations
,
March 2016 in “Journal of The American Academy of Dermatology” Finasteride's effectiveness for frontal fibrosing alopecia is uncertain.
April 2019 in “Journal of Investigative Dermatology” Frontal Fibrosing Alopecia involves disrupted cholesterol pathways, fibrosis, and increased mast cells.
April 2021 in “Aktuelle Dermatologie” Frontal Fibrosing Alopecia is a type of hair loss that mainly affects postmenopausal women, has unclear causes, and lacks evidence-based treatments.